Summit Therapeutics
SMMT
13 hedge funds and large institutions have $3.32M invested in Summit Therapeutics in 2018 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 5 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
0.08% less ownership
Funds ownership: 3.59% → 3.51% (-0.08%)
7% less funds holding
Funds holding: 14 → 13 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
49% less capital invested
Capital invested by funds: $6.54M → $3.32M (-$3.22M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$28K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$16.4K |
| 3 |
Renaissance Technologies
New York
|
+$16.2K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$15.9K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$1.09K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FFW
Fusion Family Wealth
Woodbury,
New York
|
-$64K |
| 2 |
Simplex Trading
Chicago,
Illinois
|
-$51K |
| 3 |
JP Morgan Chase
New York
|
-$34K |
| 4 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$33K |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$29K |
SMMT Hedge Fund Activity: Q4 2018 in Review
13 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q4 2018, worth a combined $3.32M — down 49% from $6.54M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of SMMT and 4 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 3 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $28K. The largest seller was Fusion Family Wealth, exiting entirely with an estimated $64K sold.
- 13 institutional investors held Summit Therapeutics (SMMT) as of Q4 2018, down from 14 in Q3 2018.
- Funds reported $3.32M of Summit Therapeutics stock for Q4 2018, down 49% quarter-over-quarter.
- 4 funds opened new Summit Therapeutics positions in Q4 2018 and 5 closed out, a net change of -1 holder.
- The largest Summit Therapeutics buyer in Q4 2018 was Citadel Advisors, an estimated $28K added.
- The largest Summit Therapeutics seller in Q4 2018 was Fusion Family Wealth, an estimated $64K sold.
Based on aggregated 13F filings for Q4 2018.